All In Biotech

Drug Trial Radar · NCT06373380

A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)

A Pilot Study Evaluating HB-200 in Patients With Positive TTMV-HPV DNA After Definitive Treatment for HPV16 Positive HNSCC

Last checked: Nov 19, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

7

Actual

Start

Apr 15, 2024

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hookipa Biotech GmbH; Naveris
First posted
Apr 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers are doing this study to find out if HB-202/HB-201 is a feasible treatment for people with HPV 16-positive head and neck squamous cell cancer (HPV 16+ HNSCC) who have received standard treatment for their disease but then tested positive for HPV 16-related tumor DNA in the blood through a test called NavDx. Participants will have no evidence of cancer on imaging scans (radiographically) or by medical examination (clinically). Past studies have shown that a positive NavDx test strongly suggests the possible presence of microscopic cancer, though we do not know if testing positive will definitely lead to the cancer coming back (recurrence). The NavDx blood test has not been approved by the FDA and is considered investigational.

Conditions

  • HPV16+ Squamous Cell Carcinoma

Interventions

  • HB-200Drug

    HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every (21 days) intravenously for 4 doses (2 doses each of HB-202 and HB-201 alternating).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluable for overall survivalTime frame: up to 3 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jersey

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey

  • Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)

    Commack, New York

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center (All Protocol Activites)

    New York, New York

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    Uniondale, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.